Aiosyn: AI-Driven Digital Pathology for Precision Diagnostics
40 pages · PDF · 18 August 2025 · Licensed single-user copy, watermarked to the buyer
€499 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
Aiosyn is a Dutch deep-tech company pioneering the use of artificial intelligence to assist clinical pathologists in diagnosing cancer and kidney diseases. Founded in 2021 as a spin-off from the Radboud University Medical Center in Nijmegen, Aiosyn emerged from one of Europe’s leading computational pathology research groups .
The company develops advanced software that can detect microscopic disease patterns in digital tissue images, aiming to make diagnostics faster and more accurate. Despite its roots in healthcare, Aiosyn’s innovations in AI and imaging position it as a dual-use technology player with implications for European strategic autonomy.
Key questions this report answers
- How does Aiosyn's AI software detect microscopic disease patterns in digital tissue images to assist pathologists diagnosing cancer and kidney diseases?
- How does Aiosyn's computational-pathology heritage from Radboud University Medical Center translate into a dual-use technology relevant to European strategic autonomy?
- Which partners, customers and markets does the Dutch deep-tech firm target for its AI and imaging innovations?
- What capability gaps, IP assets and strategic indicators define Aiosyn's dual-use potential in AI-driven diagnostics?
Inside this report
- Executive Summary
- Corporate Identity & Legal Structure
- Strategic Business Profile
- Technology Portfolio Mapping
- Technology Readiness Assessment
- European Strategic Program Participation
- Academic & Research Origins
- Dual-Use Applications & European Market Strategy
- Strategic Partnerships & European Industrial Alliances
- European Market Focus & Operational Domains
- Intellectual Property & European Innovation Assets
- Leadership & European Technical Expertise
- Capability and Gap Analysis
- Strategic Indicators & European Innovation Metrics
Who it's for
Investors screening Aiosyn, competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.
Methodology & sources
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; the report reflects them as of its publication date (18 August 2025).
Format & delivery
40-page PDF, watermarked to you (name, e-mail, order number on every page). Delivered immediately after checkout on the confirmation page and by e-mail; the personal link is valid for 72 hours and up to 5 downloads (re-issued on request). Guest checkout — no account required. Single-user licence: see the Terms of Sale.
The full analysis, not the summary
The public briefing linked above tells you what this report found; the report itself shows the full evidence and reasoning behind it, section by section. It is the complete, dated document from the DFM research desk — sources cited, delivered as a licensed PDF you can keep and cite in your own work.
Related on DFM
More Tactical reports · Computer Vision · Military Medical Tech · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →